Central serous chorioretinopathy
Conditions
Interventions
5%DC group:577nm micropulse laser
10%DC group:577nm micropulse laser
Sponsors
The First People's Hospital affiliated to Shanghai Jiao Tong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Over the age of 18, regardless of gender; 2) Clinical manifestations and multi-mode images were used to clearly diagnose active CSC eyes; 3) OCT showed fluid accumulation in the posterior macular area (within the range of 6mm in diameter). 4) The outer layers of OCT and OCTA showed no CNV image or blood flow signal; 5) BCVA >= 34 letters (equivalent to 0.1 of Snellen visual acuity chart); 6) No refractive media opacity or pupil problem affecting fundus examination, excluding other fundus lesions resulting in effusion; 7) Can sign the informed consent and complete the follow-up observation as required. Note: Only one target eye can be selected for each subject in the study. If both eyes meet the inclusion criteria, the researcher will determine the target eye from the medical point of view.
Exclusion criteria
Exclusion criteria: 1) Target eye received hormone therapy or anti-VEGF drugs, etc. < 3 months; 2) Contralateral eye BCVA < 20/200 (equivalent to 20/200 of Snellen's visual acuity chart); Myopia or 6 d; 3) There is fibrosis tissue, scar or atrophy in the fovea of the target eye, or bleeding and exudation, or vitreous membrane warts of any eye;Multi-mode image display of CNV; 4) Existing or previous ocular diseases of the target eye can affect the detection of macula, or affect the central vision (macular anterior membrane, vitreous macular traction, etc.); 5) The target eye has received ophthalmic surgery (corneal transplantation, vitrectomy, macular translocation, glaucoma surgery, total retinal photocoagulation, photodynamic therapy, etc.) and other macular surgeons; 6) Target eyes who had received cataract surgery within 3 months before screening; 7) Active eye infection (e.g., blepharitis, infectious conjunctivitis, keratitis, scleral inflammation, endophthalmitis, optic neuritis) or repeated infection in the target eye or contralateral eye; 8) Past or present glaucoma or glaucoma filtering surgery for the target eye; 9) No lens in the target eye (excluding intraocular lens) or posterior capsule rupture of the lens (except YAG laser posterior capsulorhexis after intraocular lens implantation); 10) Recent obvious cardiovascular or cerebrovascular disease or other medical history, is receiving treatment; 11) Long-term use of hormones, vasodilators or other drugs that cause fundus lesions; 12) Patients with a systemic history requiring hormone therapy or surgical treatment, or with recent stress injuries requiring invasive examinations; 13) Persons with mental disorders, alcoholism, smoking, and neurosis who are receiving or in need of treatment; 14) During pregnancy, or in preparation for pregnancy; 15) The visual acuity of patients without CSC was progressively decreased, so it was not suitable for those who needed to be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subretinal fluid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Best corrected vision;Central retinal thickness;autofluorescence;laser times; | — |
Countries
China
Contacts
Public ContactGong Yuanyuan
The First People's Hospital affiliated to Shanghai Jiao Tong University
Outcome results
None listed